Merck Sharp + Dohme Corp.

Maribel Beaumont

Robert A Kastelein

Marie-Ange Buyse

Carlo Boutton

Bruno Dombrecht

David Vlerick

Edward P Bowman

Juha Punnonen

Bjorn Victor

Edward Bowman

Rene De Waal Malefyt

Terrill K McClanahan

Jeanine D Mattson

Jennifer R Louten

The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.

PD1 and/or LAG3 binders

The present invention provides molecules, such as ISVDs and Nanobodies, that bind to CTLA4 or human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.

CTLA4 binders

The present invention provides multispecific molecules, e.g., comprising more than one ISVD or Nanobody, that bind to PD1 and CTLA4. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.

PD1/CTLA4 binders

The present invention relates to biomarker responsive to treatment with an anti-Thymic Stromal Lymphopoietin (TSLP) antibody.

Biomarkers for TSLP treatment

Growing community of inventors

San Mateo, CA, United States of America

Maribel Beaumont